Literature DB >> 21450537

The achievement of mass balance by simultaneous quantification of floxuridine prodrug, floxuridine, 5-fluorouracil, 5-dihydrouracil, α-fluoro-β-ureidopropionate, α-fluoro-β-alanine using LC-MS.

Yasuhiro Tsume1, Chester J Provoda, Gordon L Amidon.   

Abstract

5-Fluoro-2'-deoxyuridine (floxuridine, 5-FdUrd) and 5-fluorouracil (5-FU) are widely used for the treatment of colorectal cancers. The mechanisms of action of 5-FdUrd and 5-FU, as well as the biochemical pathway responsible for their metabolism, are well understood. Identification of every metabolite and achieving mass balance by conventional UV absorption-based HPLC analysis are not feasible because the metabolites beyond 5-FU in the 5-FdUrd metabolic pathway are undetectable by UV light. We therefore established a mass spectrometry method, designed for fast and convenient analysis, for simultaneously measuring 5-FdUrd, 5-FU, and their metabolites. Linearity, precision and accuracy were validated in the concentration ranges studied for each compound. Hydrolysis studies of 5-FdUrd and amino acid mono ester prodrugs of 5-FdUrd in Capan-2 cell homogenates were carried out and the achievement of mass balance was established with this method (recovery of 5'-O-l-leucyl-FdUrd was 96.6-108.2% and that of 5-FdUrd was 79.4-117.4%). This simple LC-MS method achieves reliable quantitation and mass balance of 5-FdUrd, 5-FU, and their metabolites and can be effectively utilized for further kinetic studies.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21450537      PMCID: PMC3086577          DOI: 10.1016/j.jchromb.2011.02.045

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  36 in total

Review 1.  Biochemical pharmacology and analysis of fluoropyrimidines alone and in combination with modulators.

Authors:  G Weckbecker
Journal:  Pharmacol Ther       Date:  1991       Impact factor: 12.310

2.  Cytotoxic mechanisms of 5-fluoropyrimidines. Relationships with poly(ADP-ribose) polymerase activity, DNA strand breakage and incorporation into nucleic acids.

Authors:  E Willmore; B W Durkacz
Journal:  Biochem Pharmacol       Date:  1993-07-20       Impact factor: 5.858

3.  Basis for natural variation in sensitivity to 5-fluorouracil in mouse and human cells in culture.

Authors:  J D Laskin; R M Evans; H K Slocum; D Burke; M T Hakala
Journal:  Cancer Res       Date:  1979-02       Impact factor: 12.701

4.  A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients.

Authors:  C Coustère; F Mentré; J P Sommadossi; R B Diasio; J L Steimer
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

5.  Effect of dipyridamole on fluorodeoxyuridine cytotoxicity in vitro and in cancer patients.

Authors:  A C Buzaid; D S Alberts; J Einspahr; K Mosley; Y M Peng; K Tutsch; C P Spears; H S Garewal
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 6.  Metabolism and mechanism of action of 5-fluorouracil.

Authors:  W B Parker; Y C Cheng
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

7.  Evidence for the importance of 5'-deoxy-5-fluorouridine catabolism in humans from 19F nuclear magnetic resonance spectrometry.

Authors:  M C Malet-Martino; J P Armand; A Lopez; J Bernadou; J P Béteille; M Bon; R Martino
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

8.  Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile.

Authors:  G D Heggie; J P Sommadossi; D S Cross; W J Huster; R B Diasio
Journal:  Cancer Res       Date:  1987-04-15       Impact factor: 12.701

9.  High-pressure liquid chromatographic determination of ftorafur [1-(tetrahydro-2-furanyl)-5-fluorouracil] and GLC-mass spectrometric determination of 5-fluorouracil and uracil in biological materials after oral administration of uracil plus ftorafur.

Authors:  T Marunaka; Y Umeno; K Yoshida; M Nagamachi; Y Minami; S Fujii
Journal:  J Pharm Sci       Date:  1980-11       Impact factor: 3.534

Review 10.  Clinical pharmacology of 5-fluorouracil.

Authors:  R B Diasio; B E Harris
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

View more
  5 in total

1.  Selection of suitable prodrug candidates for in vivo studies via in vitro studies; the correlation of prodrug stability in between cell culture homogenates and human tissue homogenates.

Authors:  Yasuhiro Tsume; Gordon L Amidon
Journal:  J Pharm Pharm Sci       Date:  2012       Impact factor: 2.327

2.  The development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: enhanced membrane permeability and enzymatic stability.

Authors:  Yasuhiro Tsume; Tuba Incecayir; Xueqin Song; John M Hilfinger; Gordon L Amidon
Journal:  Eur J Pharm Biopharm       Date:  2013-12-19       Impact factor: 5.571

Review 3.  A Critical Review on Clinical Application of Separation Techniques for Selective Recognition of Uracil and 5-Fluorouracil.

Authors:  Khushaboo Pandey; Rama Shankar Dubey; Bhim Bali Prasad
Journal:  Indian J Clin Biochem       Date:  2015-02-15

4.  Study of intracellular anabolism of 5-fluorouracil and incorporation in nucleic acids based on an LC-HRMS method.

Authors:  Christelle Machon; Frédéric Catez; Nicole Dalla Venezia; Floriane Vanhalle; Laetitia Guyot; Anne Vincent; Maxime Garcia; Béatrice Roy; Jean-Jacques Diaz; Jérôme Guitton
Journal:  J Pharm Anal       Date:  2020-04-07

5.  The dipeptide monoester prodrugs of floxuridine and gemcitabine-feasibility of orally administrable nucleoside analogs.

Authors:  Yasuhiro Tsume; Blanca Borras Bermejo; Gordon L Amidon
Journal:  Pharmaceuticals (Basel)       Date:  2014-01-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.